{"denoms":[{"counts":[{"groupId":"BG000","value":"337"},{"groupId":"BG001","value":"338"},{"groupId":"BG002","value":"675"}],"units":"Participants"}],"groups":[{"description":"Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).","id":"BG000","title":"Vemurafenib"},{"description":"Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).","id":"BG001","title":"Dacarbazine"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"244"},{"groupId":"BG001","value":"270"},{"groupId":"BG002","value":"514"}]}],"title":"< 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"161"}]}],"title":">=65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"137"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"294"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"200"},{"groupId":"BG001","value":"181"},{"groupId":"BG002","value":"381"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}